Chemotherapy of Hodgkin's disease;Chemotherapie des Hodgkin-Lymphoms

Tumor Diagnostik und Therapie

Volumn 17, Issue 5, 1996, Pages 161-166

  Tesch, H ^a,b   Diehl, V ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

chemotherapy; Hodgkin's disease

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LUNG TOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; RISK FACTOR; SECOND CANCER; SEXUAL DYSFUNCTION; SHORT SURVEY;

EID: 0030458315     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Diehl V: Dose escalation study for the treatment of Hodgkin's disease. Ann. Hematol. 66 (1993) 139-140
2. Loeffler M, Mauch P, MacLennan K, Specht L, Henry-Amar M: Review on prognostic factors. Ann. Oncol. 3 Suppl. 4 (1992) 63-66
3. Mauch P, Larson D, Osteen R et al.: Prognostic factors for positive surgical staging in patients with Hodgkin's disease. Ann. Oncol. 3 Suppl. 4 (1992) 257-265
4. Pavlowsky A, Maschio M, Santarelli M T et al.: Randomized triat of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. JNCl 80 (1988) 1466-1473
5. Zittoun R, Audebert A, Hoerni A et al.: EF versus IF irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J. Clin. Oncol. 3 (1985) 207-214
6. Henkelmann C G, Hagemeister F B, Fuller L M: Two cycles of MOPP and radiotherapy for stage III 1 A and III 1 B Hodgkin's disease. J. Clin. Oncol. 6 (1988) 1292-1302
7. Longo D L: The use of chemotherapy in the treatment of Hodgin's disease. Sem. Oncol. 6 (1990) 716-735
8. Horning S J, Hoppe R T, Hancock S L et al.: Vinblastine, Bleomycine and Methotrexate: an effective adjuvant in favorable Hodgkin's disease. J. Clin. Oncol. 6 (1988) 1822-1831
9. Hellman S, Jaffe E S, de Vita V T: Hodgkin's disease. Lippincott Comp., Philadelphia (1989) 1696-1740
10. Bonadonna G, Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat. Rev. 9 (1982) 21-35
11. Bonadonna G, Valagussa P, Santorano A: Alternating non-cross-resistant combination or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann. Intern. Med. 104 (1986) 739-746
12. Goldie J H, Coldmann A J, Gaudaskas G A: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treatm. Rep. 66 (1982) 439-449
13. Stetler-Stevenson M, Crush-Stanton S, Cossman J: Involvement of the bcl-2 gene in Hodgkin's disease. J. Natl. Cancer Inst. 82 (1990) 855-858
14. Connors J M: MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc ASCO 11 (1992) 1073a
15. Klimo P, Connors J M: An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Sem. Hematol. 25 (1988) 34-40
16. Cause A, Jung W, Schmits R et al.: Soluble CD8, CD25 and CD30 antigen as prognostic markers in patients with untreated Hodgkin's lymphoma. A. Oncol. 3 (1992) 49-52
17. Diehl V, Engert A: An overview on the Second International Symposium on Hodgkin's disease. Ann. Oncol. 3 Suppl. 4 (1992) 1-3
18. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's disease. A. Oncol. 3 (1992) 117-128
19. Kreuser E D, Felsenberg D, Behles C et al.: Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. A. Oncol. 3 (1992) 105-110
20. Valagussa P, Santoro A, Bonadonna G: Thyroid, Pulmonary, and cardiac sequelae after treatment for Hodgkin's disease. Ann. Oncol. 3 Suppl. 4 (1992) 111-116
21. Correa P, O'Conor GT: Epidemiologic patterns of Hodgkin's disease. Int. J. Cancer 8 (1971) 192-201